No headlines found.
BriaCell Therapeutics Announces Closing of Offering
Globe Newswire (Tue, 2-Jun 4:05 PM ET)
BriaCell Presents Positive Clinical Data at ASCO 2026
Globe Newswire (Mon, 1-Jun 7:30 AM ET)
BriaCell Therapeutics Announces Pricing of Offering
Globe Newswire (Sun, 31-May 7:59 PM ET)
Globe Newswire (Tue, 26-May 7:30 AM ET)
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026
Globe Newswire (Fri, 22-May 7:30 AM ET)
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+
Globe Newswire (Fri, 15-May 7:30 AM ET)
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer
Globe Newswire (Thu, 14-May 7:30 AM ET)
Globe Newswire (Wed, 13-May 7:30 AM ET)
BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients
Globe Newswire (Tue, 12-May 7:30 AM ET)
Globe Newswire (Thu, 7-May 7:30 AM ET)
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Briacell Therapeutics Corp. - Warrant trades on the NASDAQ stock market under the symbol BCTXZ.
As of June 18, 2026, BCTXZ stock price was flat at $0.08 with 1,525 million shares trading.
BCTXZ has a beta of 3.86, meaning it tends to be more sensitive to market movements. BCTXZ has a correlation of 0.09 to the broad based SPY ETF.
BCTXZ has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
BCTXZ has underperformed the market in the last year with a return of -91.8%, while the SPY ETF gained +26.9%. In the last 3 month period, BCTXZ fell short of the market, returning -38.7%, while SPY returned +13.5%. However, in the most recent 2 weeks BCTXZ has outperformed the stock market by returning 0.0%, while SPY returned -1.1%.
BCTXZ support price is $.07 and resistance is $.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTXZ shares will trade within this expected range on the day.